Small cell carcinoma(SCC) of prostate is a rarely seen agressive tumor.[1,2]It accounts for%0.5-2 of all prostate cancers.[3]SCC usually originates from lung but sometimes it may originate from different sites outside the lung that is called extrapulmonary small cell carcinoma.[4]Generally, small cell carcinoma of the prostate is symptomatic at diagnosis unlikely adenocarcinoma.[3]Usually there are obstructive, neurologic symptoms and also symptoms related with paraneoplastic syndroms or metastasis would be seen.[1,3,5]In this study we aimed to present the case with small cell carcinoma of prostate, the treatment and follow-up results of the patient.

Case

81 year-old male patient was admitted to our clinic with obstructive symptoms and dysuria. The patient didn’t benefit from the alpha-blocker treatment and according to the uroflowmetry result, maximum flow rate was 9.5 ml/sn, average flow rate was 5.1 ml/sn. According to the ultrasonography result, prostate was 55 gr, upper urinary tract was normal. Total PSA level was 0.4 ng/ml. Digital rectal examination revaled average-size prostate and wide-spread nodules for both lobes. Transurethral resection of prostate was performed for the patient due to the obstructive symptoms. The pathology result was; small cell carcinoma of prostate, lymphovascular invasion⁺, chromogranin⁺, synaptophysin⁺. Chromogranin level was 165nmol/l,  Calcitonin level was 2ng/l,  ACTH level was 22.3pmol/l, CEA level was 6.03ng/ml. The histopathologic examination revealed diffuse infiltrative, single-cell or group patterns with minimal cytoplasm and nuclear molding.(Figüre 1) Immunohistochemical study revealed; EMA⁽⁺⁾, PSA^(-), AMACR^(-), CK7^(-), CK20^(-), Chromogranin⁽⁺⁾, Synaptophysin⁽⁺⁾, TTF1^(-).  According to postoperative thorax computerised tomography, there were bilateral fibrotic changes in the apical lung area and spesific patchy opacities. Also according to abdominal computerised tomography, multiple hypodense lesions compatible with metastasis in the liver and pancreas.(Figure 2) Positron emission tomography revealed involvements in prostate gland, bladder and rectum compatible with the invasion of primary pathologic focus, involvements in bilateral internal iliac, bilateral common iliac, presacral, parailiac and right external iliac lymph nodes and in liver, surrenal glands, bone tissue compatible with metastasis.(Figure 3) Bone scan revealed metastatic involvements in left 8-10 costovertebral junctions, 1st and 11th costa, 9th vertebral. After the examinations, the patient was consulted to medical oncology for chemoterapy.

Discussion

Prostate is one of the most extrapulmonary site of  small cell  carcinoma [6].Small cell carcinoma of prostate is poor-prognosis tumor prone to early systemic metastasis and mostly diagnosed at advanced stage[7].Most of the patients are in advanced stage when they are diagnosed [7].Some cases were reported to be diagnosed as ‘Gleason pattern 5’ in the literature[6-8]. In some cases symptoms related with ACTH production were reported[5,9]. Also KIT, pan-cytokeratin, p53, Ki-67, PSA(prostate spesific antigene), alpha-methylacyl-CoA racemase and PDGFRA(platelet-derived growth factor-α) gene mutations were reported for some cases[10,11]. Neuron-spesific enolase(NSE) levels would be elevated of the patients[12]. PSA levels are lower and in normal range for most of the patients[3,5,13]. Computerised tomography(CT) and positron emission tomography(PET) would be used for imaging[5]. During the histopathologic examination, argentaffin or argyrophil cells would be seen[9].The classic morphology is ‘oat cell’ morphology[14].Urogenital small cell carcinomas are usually high grade and poor differantiation[4]. They have poor prognosis and survival is less than 1 year for most of the cases[4].There is no standart treatment for now[12].Chemoterapy and radiotherapy would be used for treatment. Cisplatin and etoposide are common recommended chemotherapeuticsand sometimes doxorubicin would be added [3,15].Extrapulmonary small cell cracinomas are less chemosensitive than pulmonary small cell carcinomas[4]. Successful treatments were reported in the literature. Also for local disease radiotherapy would be used for treatment. In our study, patient was diagnosed as small cell carcinoma with multiple metastases and after the diagnosis the patient was consulted to medical oncology for chemotherapy.

Figure 1: Diffuse infiltration to muscle layer / Single-cell and group pattern/ Nuclear molding. EMA(+), PSA(-), AMACR(-), CK7(-), CK20(-), Chromogranin(+), Synaptophysin(+), TTF1(-).

Figure 2: Computerised Tomography.

Figure 3: Positron Emission Tomography

1. Demirtas A, Sahin N, Ozturk F, Akinsal EC, Demirtas T et al. (2013) Small cell prostate carcinoma: a case report and review of the literature. Case reports in urology 2013:387931.
2. Deorah S, Rao MB, Raman R, Gaitonde K, Donovan JF (2012) Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study. BJU international 109:824-830.
3. Anker CJ, Dechet C, Isaac JC, Akerley W, Shrieve DC (2008) Small-cell carcinoma of the prostate. Journal of clinical26:1168-1171.
4. Tabrizipour AI, Shen L, Mansberg R, Chuong B (2016) Extrapulmonary Small Cell Carcinoma of the Seminal Vesicles and Prostate Demonstrated on 18F-FDG Positron Emission Tomography/Computed Tomography. Molecular imaging and radionuclide therapy 25:47-49.
5. Rueda-Camino JA, Losada-Vila B, De Ancos-Aracil CL, Rodriguez-Lajusticia L, Tardio JC, et al. (2016) Small cell carcinoma of the prostate presenting with Cushing Syndrome. A narrative review of an uncommon condition. Annals of medicine 48:293-299.
6. Wang L, Davidson DD, Montironi R, Lopez-Beltran A, Zhang S, et al. (2015) Small cell carcinoma of the prostate: molecular basis and clinical implications. Histology and histopathology 30:413-424.
7. Umar SA, Umar SA, MacLennan GT (2009) Small cell carcinoma of the prostate. The Journal of urology181:838-839.
8. Yamamoto N, Kinoshita H, Inoue T, Kawakita S, Oguchi N, Muguruma K, et al. [Small cell carcinoma of the prostate: a case report]. Hinyokika kiyo Acta urologica Japonica. 2007;53:665-9.
9. Sarma DP and Weilbaecher TG (1989) Small-cell carcinoma of prostate. Urology 33:332-335.
10. Terada T (2012) Small cell neuroendocrine carcinoma of the prostate: incidence and a report of four cases with an examination of KIT and PDGFRA. The Prostate 72:1150-1156.
11. Terada T (2014) Primary small cell carcinoma of prostate without immunoreactive neuroendocrine proteins but with expressions of KIT and platelet-derived growth factor-alpha. International journal of urology : official journal of the Japanese Urological Association 22:122-124.
12. Hirai M, Konishi T, Saito K, Washino S, Kobayashi Y, et al. (2015) [Small Cell Carcinoma of the Prostate: A Case Report of RelativThe minimum amount to withdraw is 0.0002 BTC. Please mine more bitcoins!
    e Long-Term Survival]. Nihon Hinyokika Gakkai zasshi The japanese journal of urology 106:280-284.
13. Horie K, Kameyama K, Mizutani K, Sugawara T, Seike K, et al. (2014) [Small cell carcinoma of the prostate effectively treated for relatively long term: a case report]. Hinyokika kiyo Acta urologica Japonica 60:517-521.
14. Wang W, Epstein JI (2008) Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. The American journal of surgical pathology 32:65-71.
15. Stein ME, Bernstein Z, Abacioglu U, Sengoz M, Miller RC,et al. (2008) Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications–a retrospective study of 30 patients from the rare cancer network. The American journal of the medical sciences 336:478-488.

Citation: Sarikaya S, Ozbek R, Senocak C, Simsek GG, Bozkurt OF, et al. (2016) Small Cell Carcinomaof Prostate: Case study and review of the literature. J Urol Renal Dis 2016: 101. DOI: 10.29011/2575-7903.000101.